Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
QuintilesIMS
Farmers Insurance
Baxter
Citi
Accenture
Cantor Fitzgerald
Moodys
Merck

Generated: June 18, 2018

DrugPatentWatch Database Preview

SANSERT Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Sansert patents expire, and when can generic versions of Sansert launch?

Sansert is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in SANSERT is methysergide maleate. Additional details are available on the methysergide maleate profile page.
Summary for SANSERT
Drug patent expirations by year for SANSERT
Medical Subject Heading (MeSH) Categories for SANSERT
Synonyms for SANSERT
(+)-N-((1-Hydroxymethyl)propyl)-1-methyl-D-lysergamide bimaleate
(2Z)-BUT-2-ENEDIOIC ACID; (4R,7R)-N-[(2S)-1-HYDROXYBUTAN-2-YL]-6,11-DIMETHYL-6,11-DIAZATETRACYCLO[7.6.1.0(2),?.0(1)(2),(1)?]HEXADECA-1(16),2,9,12,14-PENTAENE-4-CARBOXAMIDE
[8?(S)]-9,10-Didehydro-N-[1-(hydroxymethyl)propyl]-1,6-dimethylergoline-8-carboxamide maleate
[8beta(S)]-9,10-Didehydro-N-[1-(hydroxymethyl)propyl]-1,6-dimethylergoline-8-carboxamide maleate
1-(Hydroxymethyl)propylamide of 1-methyl-(+)-lysergic acid hydrogen maleate
1-Methyl-D-lysergic acid butanolamide dimaleate
1257-58-5
129-49-7
29605-96-7
2U7H1466GH
32537-90-9
52502-68-8
87387-76-6
9,10-Didehydro-N-(1-(hydroxymethyl)propyl)-1,6-dimethylergoline-8beta-carboxamide maleate (1:1) (salt)
AKOS024456362
AN-23038
C21H28N3O2.C4H3O4
C25H31N3O6
CCG-213467
CHEBI:6894
CHEMBL1200938
D00681
Deseril-retard
Desernil bismaleate
EINECS 204-950-9
Ergoline-8-beta-carboxamide, 9,10-didehydro-N-(1-(hydroxymethyl)propyl)-1,6-dimethyl-, maleate (1:1) (salt)
Ergoline-8-beta-carboxamide, 9,10-didehydro-N-(1-(hydroxymethyl)propyl)-1,6-dimethyl-,maleate (1:1) (salt)
Ergoline-8-carboxamide, 9,10-didehydro-N-((1S)-1-(hydroxymethyl)propyl)-1,6-dimethyl-, (8beta)-, (2Z)-2-butenedioate (1:1) (salt)
Ergoline-8-carboxamide, 9,10-didehydro-N-(1-(hydroxymethyl)propyl)-1,6-dimethyl-, (8beta)-, (Z)-2-butenedioate (1:1) (salt)
Ergoline-8-carboxamide, 9,10-didehydro-N-[(1S)-1- (hydroxymethyl)propyl]-1,6-dimethyl-, (8ss)-, (2Z)-2-butenedioate (1:1) (salt)
Ergoline-8beta-carboxamide, 9,10-didehydro-N-(1-(hydroxymethyl)propyl)-1,6-dimethyl-, maleate (1:2) (salt)
Ergoline-8beta-carboxamide, 9,10-didehydro-N-(1-(hydroxymethyl)propyl)-1,6-dimethyl-, maleate (1:2) (salt) (8CI)
EU-0100863
HMS2093N13
HMS2231L15
HMS3262N07
LP00863
LS-64362
LWYXFDXUMVEZKS-ZVFOLQIPSA-N
Lysergamide, N-((1-hydroxymethyl)propyl)-1-methyl-, maleate
M-137
Methysergide bimaleate
Methysergide dimaleate
Methysergide hydrogen maleate
Methysergide maleate
Methysergide maleate (USP)
Methysergide maleate [USAN]
Methysergide maleate salt
Methysergide maleate salt, solid
Methysergide maleate, United States Pharmacopeia (USP) Reference Standard
MFCD00083185
MLS000069364
MLS001076153
MolPort-003-958-638
NCGC00261548-01
NSC 186061
NSC-759143
NSC759143
Pharmakon1600-01505492
PL009422
regid855989
Sansert (TN)
SMR000058483
SMR000653472
Tox21_500863
UNII-2U7H1466GH

US Patents and Regulatory Information for SANSERT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis SANSERT methysergide maleate TABLET;ORAL 012516-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Cantor Fitzgerald
Argus Health
Teva
Boehringer Ingelheim
Fuji
Fish and Richardson
Cerilliant
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.